Background: Prion disease research and surveillance can be challenging due to the disease’s difficulty to diagnose, rapid progression, and geographic dispersion. Improving accessibility through teleneurology could improve the ability to conduct these activities. Objectives: The aim of this study was to determine the feasibility of conducting teleneurology assessments for research and surveillance of prion diseases. Method: Participants were offered in-person visit, medical record review, or teleneurology assessment. Standardized histories and assessments evaluating cognition, functional ability, and neuropsychiatric symptoms were collected. Data regarding participants’ satisfaction with teleneurology were collected. Results: From April 2017 to July 2018, the study received 114 referrals. 45 and 5 participants consented for the teleneurology and medical record review arms of the study, respectively. 29 subjects participated in at least one teleneurology visit. Participants expressed satisfaction with teleneurology and found it easy to participate. Some aspects of the examination were hindered or interrupted due to technological reasons. Conclusions: We demonstrate the feasibility and preference of teleneurology as a modality in which subjects with prion disease can partake in clinical research. Technological aspects sometimes interfered with research assessments.

1.
World Health Organization
.
Global surveillance, diagnosis and therapy of human Transmissible Spongiform Encephalopathies: Report of a WHO consultation
.
Geneva
:
World Health Organization
;
1998
.
2.
CDC’s Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD)
.
2018
[Internet]. httpswwwcdcgovprionscjddiagnostic-criteriahtml [cited 2018 Oct 28];Available from: https://www.cdc.gov/prions/cjd/diagnostic-criteria.html
3.
Paterson
RW
,
Torres-Chae
CC
,
Kuo
AL
,
Ando
T
,
Nguyen
EA
,
Wong
K
, et al
Differential diagnosis of Jakob-Creutzfeldt disease
.
Arch Neurol
.
2012
Dec
;
69
(
12
):
1578
82
.
[PubMed]
0003-9942
4.
Appleby
BS
,
Rincon-Beardsley
TD
,
Appleby
KK
,
Crain
BJ
,
Wallin
MT
.
Initial diagnoses of patients ultimately diagnosed with prion disease
.
J Alzheimers Dis
.
2014
;
42
(
3
):
833
9
.
[PubMed]
1387-2877
5.
Wechsler
LR
.
Advantages and limitations of teleneurology
.
JAMA Neurol
.
2015
Mar
;
72
(
3
):
349
54
.
[PubMed]
2168-6149
6.
Schneider
RB
,
Biglan
KM
.
The promise of telemedicine for chronic neurological disorders: the example of Parkinson’s disease
.
Lancet Neurol
.
2017
Jul
;
16
(
7
):
541
51
.
[PubMed]
1474-4422
7.
Agnihotri
SP
,
Koralnik
IJ
.
Training for a neurology career in a rare disease: the role of cyberconsults
.
Ann Neurol
.
2015
May
;
77
(
5
):
738
40
.
[PubMed]
0364-5134
8.
Carswell
C
,
Rañopa
M
,
Pal
S
,
Macfarlane
R
,
Siddique
D
,
Thomas
D
, et al
Video Rating in Neurodegenerative Disease Clinical Trials: the Experience of PRION-1
.
Dement Geriatr Cogn Disord Extra
.
2012
Jan
;
2
(
1
):
286
97
.
[PubMed]
1664-5464
9.
Zerr
I
,
Kallenberg
K
,
Summers
DM
,
Romero
C
,
Taratuto
A
,
Heinemann
U
, et al
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease
.
Brain
.
2009
Oct
;
132
(
Pt 10
):
2659
68
.
[PubMed]
0006-8950
10.
Foutz
A
,
Appleby
BS
,
Hamlin
C
,
Liu
X
,
Yang
S
,
Cohen
Y
, et al
Diagnostic and prognostic value of human prion detection in cerebrospinal fluid
.
Ann Neurol
.
2017
Jan
;
81
(
1
):
79
92
.
[PubMed]
0364-5134
11.
Brandt
J
,
Spencer
M
,
Folstein
M
.
The Telephone Interview for Cognitive Status
.
Neuropsychiatry Neuropsychol Behav Neurol
.
1988
;
1
:
111
7
.0894-878X
12.
Thompson
AG
,
Lowe
J
,
Fox
Z
,
Lukic
A
,
Porter
MC
,
Ford
L
, et al
The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies
.
Brain
.
2013
Apr
;
136
(
Pt 4
):
1116
27
.
[PubMed]
0006-8950
13.
Cummings
JL
,
Mega
M
,
Gray
K
,
Rosenberg-Thompson
S
,
Carusi
DA
,
Gornbein
J
.
The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia
.
Neurology
.
1994
Dec
;
44
(
12
):
2308
14
.
[PubMed]
0028-3878
14.
Mead
S
,
Burnell
M
,
Lowe
J
,
Thompson
A
,
Lukic
A
,
Porter
MC
, et al
Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease
.
JAMA Neurol
.
2016
Apr
;
73
(
4
):
447
55
.
[PubMed]
2168-6149
15.
Parchi
P
,
Giese
A
,
Capellari
S
,
Brown
P
,
Schulz-Schaeffer
W
,
Windl
O
, et al
Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects
.
Ann Neurol
.
1999
Aug
;
46
(
2
):
224
33
.
[PubMed]
0364-5134
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.